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We assessed the effect of fluconazole 1200mg/day
on the QT interval in cryptococcal meningitis
patients. Mean corrected QT (QTc) change from
baseline to day 7was 10.1ms (IQR:S28 to 46ms) in
the fluconazole treatment group and S12.6ms
(IQR: S39 to 13.5ms) in those not taking flucona-
zole (PU 0.04). No significant increase in QTc
measurements over 500ms was observed with flu-
conazole. Nevertheless, it remains important to
correct any electrolyte imbalance and avoid con-
comitant drugs that may increase QTc.
Fluconazole remains in routine use as an induction
regimen for the treatment of cryptococcal meningitis in
many low and middle income countries, either alone, or
in combination with amphotericin B. Guidelines
recommend dosages of 800–1200 mg/day [1–3]. How-
ever, it has been previously suggested that fluconazole
may prolong QT interval, either directly, or by inhibiting
the hepatic metabolism of other QT-prolonging agents
[4,5]. A lengthened heart rate-corrected QT (QTc)
interval is a biomarker for ventricular tachyarrhythmias
such as torsades de pointes and is a risk factor for sudden
death, particularly in older patients [6]. In a prior study of
cryptococcal meningitis, patients receiving amphotericin
B with fluconazole (800 mg/day) had a slight increase
in QTc compared with baseline (mean change from
baseline: 6.6 ms (95% confidence interval 3.2 to
16.4 ms]) [4]. However, overall, day 7 QTc intervals
for those treated with amphotericin B with fluconazole
(800 mg/day) were similar compared with patients treated
with amphotericin B in combination with fluconazole, at
the lower dose of 400 mg/day, and amphotericin B alone;
and there was no suggestion of an increase in the risk of
clinically significant QTc prolongation (>500 ms) [4].
We assessed the effect of a fluconazole dose of 1200 mg/
day, on QTc interval in a cohort of patients enrolled in the
Advancing Cryptococcal meningitis Treatment for Africa
(ACTA) trial. This was a phase III trial for the treatment of
HIV-associated cryptococcal meningitis in Africa testing
five different treatment regimens, three of which containedDOI:10.1097/QAD.0000000000001961
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original work is properly cited.fluconazole at 1200 mg/day dosage [7]. ECGs to measure
the QTc (using Bazett’s formula) were performed for all
participants at baseline and 1 week after enrolment, for the
first 22 months of the study, until the Data Monitoring
Committee recommended to discontinue routine ECG
monitoring on the basis that the clinical risk did not
warrant such monitoring in this context.
QTc results from patients randomized to regimens
including fluconazole, 1200 mg/day (oral treatment of
fluconazole with flucytosine for 2 weeks; amphotericin B
with fluconazole for 1 week, and amphotericin B with
fluconazole for 2 weeks, 2/3 of those enrolled in the trial)
were compared with those randomized to non-flucona-
zole-containing regimens (amphotericin B with flucy-
tosine for 1 week and amphotericin B with flucytosine for
2 weeks, 1/3 of those enrolled). Mean QTc length in each
of the two groups at day 7 was compared by analysis of
covariance (ANCOVA), adjusting for baseline QTc
measurement. Mean change in QTc length from baseline
to day 7 was analysed using a t-test and the proportion of
patients with a long QTc (500 ms) in each group was
compared at day 7 using Fisher’s exact test. Analyses were
performed using Stata, version 14.1 (StataCorp, College
Station, Texas, USA).
A total of 150 patients had QTc results recorded at
baseline with 104 (69.3%) randomized to a high-dose
fluconazole treatment regimen. As expected, there was
no significant difference in mean QTc length for patients
randomized to fluconazole treatment compared with
those randomized to no fluconazole at baseline (412.9 and
414.2 ms, respectively, P¼ 0.88). At baseline, 15 patients
(10%) had Grade 1 (450–480 ms), six patients (4%) had
Grade 2 (480–490 ms) and seven patients (4.67%) had
Grade 3 QTc (>500 ms) at baseline. Of the patients with
Grade 3 QTc at baseline, six resolved (<450 ms) by day 7
with electrolyte replacement and avoidance of known
QT-prolonging concomitant drugs. Fluconazole was
withheld temporarily for two patients. One patient with
severe cryptococcal meningitis and sepsis died prior to a
follow-up ECG.
Following commencement of antifungal treatment, QTc
was recorded for 125 patients at day 7 with 84 (67.2%)
randomized to high-dose fluconazole. Sixteen patients
(12.8%) had Grade 1 (450–480 ms), eight patients (6.4%)
had a Grade 2 (480–490 ms) and one patient (0.8%) had a
Grade 3 QTc (>500 ms) at day 7. The patient with Grade
3 QTc had a normal QTc at baseline (437 ms) that
increased at day 7 to 505 ms and this patient was
randomized to a fluconazole-containing treatmentwer Health, Inc. This is an open access article distributed under the
ted use, distribution, and reproduction in any medium, provided the
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Table 1. Corrected QT interval measurements at baseline and day 7 by treatment group.
Day 7 Mean change from baseline to day 7
(n¼113)
(n¼113) (n¼125)
Treatment group Mean QTc, ms (IQR) Long QTc, ms, n (%) Mean change, ms (IQR)
Fluconazole 422.5 (401–448.5) 1 (1.0%) 10.1 (28 to 46)
No fluconazole 402.1 (385–443) 0 12.6 (39 to 13.5)
P value 0.01a 1.0b 0.04c
Overall 415.8 (390–444) 1 (0.8%) 2.9 (30 to 37)
IQR, interquartile range; QTc, corrected QT.
aANCOVA analysis adjusting for baseline QTc.
bFisher’s exact test.
ct-test.regimen. The patient was well on discharge at day 14 of
the study and completed 10-week follow-up without
further adverse events. Overall mean QTc length at day 7
was 415.8 ms (IQR: 390–444). The mean change in
QTc length from baseline was 2.9 ms (IQR: 30 to
37 ms): 10.1 ms (IQR: 28 to 46 ms) in the fluconazole
containing treatment group compared with 12.6 ms
(IQR: 39 to 13.5 ms) in those not taking fluconazole
(P¼ 0.04; Table 1). There was evidence for a difference
in mean QTc length for patients taking fluconazole
treatment compared with those not taking fluconazole
(422.5 and 402.1 ms, respectively, P¼ 0.01), adjusting
for baseline QTc length. However, there was no
evidence for a difference in the number of patients with
long QTc (>500 ms) between the two groups at day 7
(one patient had a long QTc in the fluconazole group
compared with none in the non-fluconazole group,
P¼ 1.0; Table 1).
A small increase in mean QTc length for patients
taking high-dose fluconazole (1200 mg/day) was
observed in this study, as shown previously for doses
of 800 mg/day [4]. As in the prior study, there was no
evidence for an increase in the proportion of patients
developing a clinically significant prolonged QTc
interval. Since our study was conducted, preliminary
results of a phase II trial using even higher fluconazole
doses (1600 and 2000 mg/day) have been reported,
without, as yet, details of QT interval effects but with
no mention of serious concerns over QT interval
prolongation [8].
Our study suggests that a fluconazole dose of 1200 mg/
day does not lead to a clinically significant lengthening of
the QTc interval and that ECG monitoring need not be
mandatory in this population, treated at this dose for
short periods. However, it is important to emphasize, as
with all drugs with the potential to prolong QT interval,
that it remains important to monitor and correct
any electrolyte imbalance and to avoid, wherever
possible, concomitant drugs that may also cause QTc
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